CLAIMS

1. A crystalline form which is a co-crystal of (3S)-2-[(5-amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl]-1'-but-2-ynyl-6-fluoro-spiro[isoindoline-3,3'-pyrrolidine]-1,2'-dione:



Compound (I), and adipic acid in a 2:1 ratio (Compound (I) Form A).

2. The crystalline form according to claim 1, wherein the crystalline form has an X-ray powder diffraction pattern containing specific peaks at (±0.2) 8.9, 19.1, 19.7 and 22.9 degrees 2-theta when measured using CuKα radiation.

3. The crystalline form according to claim 1 or 2, wherein the crystalline form has an X-ray powder diffraction pattern containing specific peaks at (±0.2) 8.9, 14.5, 16.9, 17.4, 19.1, 19.7, 21.2, 22.9, 23.7 and 25.8 degrees 2-theta when measured using CuKα radiation.

4. The crystalline form according to any one of claims 1 to 3, wherein the crystalline form has an X-ray powder diffraction substantially as shown in Figure 1 when measured using CuKα radiation.

5. The crystalline form according to any one of claims 1 to 4, wherein the crystalline form has a DSC thermogram substantially as shown in Figure 3.

6. The crystalline form according to claim 1, wherein the crystalline form is a co-crystal of (3S)-2-[(5-amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl]-1'-but-2-ynyl-6-fluoro-spiro[isoindoline-3,3'-pyrrolidine]-1,2'-dione:



Compound (I),

and adipic acid in a 2:1 ratio (Compound (I) Form A), having at least one of the following:

a) an X-ray powder diffraction pattern containing specific peaks at (±0.2) 8.9, 19.1, 19.7 and 22.9 degrees 2-theta when measured using CuKα radiation;

b) an X-ray powder diffraction pattern containing specific peaks at (±0.2) 8.9, 14.5, 16.9, 17.4, 19.1, 19.7, 21.2, 22.9, 23.7 and 25.8 degrees 2-theta when measured using CuKα radiation;

c) an X-ray powder diffraction pattern substantially as shown in Figure 1;

d) a DSC thermogram with an onset melting at 216.6°C plus or minus 5°C and a peak at 217.7°C plus or minus 5°C;

e) a DSC thermogram and optionally a TGA thermogram substantially as shown in Figure 3.

7. A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 6 and at least one pharmaceutically acceptable excipient.

8. The crystalline form according to any one of claims 1 to 6 or the pharmaceutical composition according to claim 7, for use as a medicament, for example in the prophylaxis or treatment of a disorder mediated by PRMT5.

9. Use of the crystalline form according to any one of claims 1 to 6 or the pharmaceutical composition according to claim 7, in the manufacture of a medicament, for example for the prophylaxis or treatment of a disorder mediated by PRMT5.

10. The crystalline form for use, pharmaceutical composition for use or use according to claim 8 or 9, wherein the disorder is cancer.

11. The crystalline form for use, pharmaceutical composition for use or use according to claim 10, wherein the cancer is a MTAP deleted cancer.

12. The crystalline form for use, pharmaceutical composition for use or use according to claim 10 or 11, wherein the cancer is selected from gastric, pancreatic, colorectal, uterine, bile duct, stomach, bladder, cervical, testicular germ cell, lung (e.g. non-small cell lung cancer), multiple myeloma, lymphoma (e.g. diffuse large B cell lymphoma or Hodgkin's lymphoma), rhabdomyosarcoma and cutaneous squamous cell carcinoma.